Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans - PubMed (original) (raw)
doi: 10.1097/FPC.0b013e32834282b8.
Young Koo Jee, Yon-Soo Kim, Chang Hwa Lee, Jae-Woo Jung, Sae Hoon Kim, Heung-Woo Park, Yoon-Seok Chang, In-Jin Jang, Sang-Heon Cho, Kyung-Up Min, Sang-Heon Kim, Kyung Wha Lee; Adverse Drug Reaction Research Group in Korea
Affiliations
- PMID: 21301380
- DOI: 10.1097/FPC.0b013e32834282b8
Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans
Hye-Ryun Kang et al. Pharmacogenet Genomics. 2011 May.
Erratum in
- Pharmacogenet Genomics. 2012 Aug;22(8):652
Abstract
Recent investigations suggest genetic susceptibility of allopurinol-induced severe cutaneous adverse reactions (SCARs). However, the strength of association was variable according to phenotypes and ethnic backgrounds. To explore genetic markers for allopurinol-induced SCARs in Koreans, we genotyped human leukocyte antigen (HLA) class I alleles of 25 cases of allopurinol-induced SCARs (20 cases of drug-induced hypersensitivity syndrome and five cases of Stevens-Johnson syndrome/toxic epidermal necrolysis) and 57 patients tolerant to allopurinol. Frequencies of B*5801 [92.0 vs. 10.5%, P(c)=2.45×10(-11), odds ratio (OR)=97.8], Cw*0302 (92.0 vs. 12.3%, P(c)=9.39×10(-11), OR=82.1), and A*3303 (88.0 vs. 26.3%, P(c)=3.31×10(-6), OR=20.5) were significantly higher in SCARs compared with tolerant controls. In contrast, A*0201 was not found in SCARs patients despite relatively high frequency in tolerant controls (29.8%). We found strong positive association of HLA-B*5801 and negative association of HLA-A*0201 with the development of allopurinol-induced SCARs in the Korean population.
Similar articles
- Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
van Nguyen D, Chu HC, Vidal C, Fulton RB, Nguyen NN, Quynh Do NT, Tran TL, Nguyen TN, Thu Nguyen HT, Chu HH, Thanh Thuc HT, Minh Le HT, van Nunen S, Anderson J, Fernando SL. van Nguyen D, et al. Pharmacogenomics. 2021 Jan;22(1):1-12. doi: 10.2217/pgs-2019-0146. Epub 2020 Dec 24. Pharmacogenomics. 2021. PMID: 33356553 - Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.
Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT. Hershfield MS, et al. Clin Pharmacol Ther. 2013 Feb;93(2):153-8. doi: 10.1038/clpt.2012.209. Epub 2012 Oct 17. Clin Pharmacol Ther. 2013. PMID: 23232549 Free PMC article. - Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Tassaneeyakul W, et al. Pharmacogenet Genomics. 2009 Sep;19(9):704-9. doi: 10.1097/FPC.0b013e328330a3b8. Pharmacogenet Genomics. 2009. PMID: 19696695 - HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI. Yeo SI. Int J Rheum Dis. 2013 Jun;16(3):254-7. doi: 10.1111/1756-185X.12050. Epub 2013 Apr 26. Int J Rheum Dis. 2013. PMID: 23981744 Review. - Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu KH, Yu CY, Fang YF. Yu KH, et al. Int J Rheum Dis. 2017 Sep;20(9):1057-1071. doi: 10.1111/1756-185X.13143. Epub 2017 Aug 31. Int J Rheum Dis. 2017. PMID: 28857441 Review.
Cited by
- Allopurinol: Clinical Considerations in the Development and Treatment of Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Other Associated Drug Reactions.
Dillman KM, Hawkins AM, Ragland AR, Wester GC, Greene DR, Varrassi G, Moore P, Behara R, Ahmadzadeh S, Siddaiah H, Shekoohi S, Kaye AD. Dillman KM, et al. Cureus. 2024 Jul 16;16(7):e64654. doi: 10.7759/cureus.64654. eCollection 2024 Jul. Cureus. 2024. PMID: 39149682 Free PMC article. Review. - Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population.
Chou WH, Chen LC, Wong HS, Chao CH, Chu HW, Chang WC. Chou WH, et al. Biomark Res. 2024 May 3;12(1):46. doi: 10.1186/s40364-024-00591-z. Biomark Res. 2024. PMID: 38702819 Free PMC article. - Influence of pharmacogenomic polymorphisms on allopurinol-induced cutaneous adverse drug reactions in Thai patients.
Sornsamdang G, Satapornpong P, Jinda P, Jantararoungtong T, Koomdee N, Tempark T, Klaewsongkram J, Rerkpattanapipat T, Rerknimitr P, Tuchinda P, Chularojanamontri L, Tovanabutra N, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Srisuttiyakorn C, Srinoulprasert Y, John S, Biswas M, Sukasem C. Sornsamdang G, et al. BMC Med Genomics. 2024 Apr 23;17(1):101. doi: 10.1186/s12920-024-01874-y. BMC Med Genomics. 2024. PMID: 38654296 Free PMC article. - Investigating the genetic makeup of the major histocompatibility complex (MHC) in the United Arab Emirates population through next-generation sequencing.
Marzouka NAD, Alnaqbi H, Al-Aamri A, Tay G, Alsafar H. Marzouka NAD, et al. Sci Rep. 2024 Feb 9;14(1):3392. doi: 10.1038/s41598-024-53986-1. Sci Rep. 2024. PMID: 38337023 Free PMC article. - HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature.
Liao JM, Zhan Y, Zhang Z, Cui JJ, Yin JY. Liao JM, et al. Front Pharmacol. 2023 Nov 9;14:1288068. doi: 10.3389/fphar.2023.1288068. eCollection 2023. Front Pharmacol. 2023. PMID: 38027017 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials